CN104127421B - The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone - Google Patents
The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone Download PDFInfo
- Publication number
- CN104127421B CN104127421B CN201410375041.9A CN201410375041A CN104127421B CN 104127421 B CN104127421 B CN 104127421B CN 201410375041 A CN201410375041 A CN 201410375041A CN 104127421 B CN104127421 B CN 104127421B
- Authority
- CN
- China
- Prior art keywords
- cleistanone
- anemia
- piperidyl
- ethyl derivative
- low property
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XURLTFUKDPZAPN-QFIPXVFZSA-N Cleistanone Natural products O(C)[C@H]1OC(=O)c2c(-c3cc4OCOc4cc3)c3c(c(O)c12)cc(OC)c(OC)c3 XURLTFUKDPZAPN-QFIPXVFZSA-N 0.000 title claims abstract description 70
- GEIFQLXIDUDMNZ-PCJVTFPHSA-N (4aR,4bR,6aR,8S,10aR,10bR,12R,12aR)-12-hydroxy-1,1,1',1',4a,10a,10b-heptamethyl-3'-methylidenespiro[3,4,4b,5,6,6a,7,9,10,11,12,12a-dodecahydrochrysene-8,2'-cyclopentane]-2-one Chemical compound CC1(C)CCC(=C)[C@@]11C[C@@H](CC[C@H]2[C@]3(C[C@@H](O)[C@H]4C(C)(C)C(=O)CC[C@@]42C)C)[C@@]3(C)CC1 GEIFQLXIDUDMNZ-PCJVTFPHSA-N 0.000 title claims abstract description 67
- 208000007502 anemia Diseases 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- -1 (piperidyl) ethyl Chemical class 0.000 claims abstract description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 210000003743 erythrocyte Anatomy 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002607 hemopoietic effect Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241001597008 Nomeidae Species 0.000 description 6
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 208000035126 Facies Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000035220 Dyserythropoietic Congenital Anemia Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000004440 congenital dyserythropoietic anemia Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000010437 erythropoiesis Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- 241000785597 Cleistanthus Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ODJZWVFLHZHURI-UHFFFAOYSA-M [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] Chemical compound [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] ODJZWVFLHZHURI-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- SISAYUDTHCIGLM-UHFFFAOYSA-N bromine dioxide Inorganic materials O=Br=O SISAYUDTHCIGLM-UHFFFAOYSA-N 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to O (piperidyl) ethyl derivative of Cleistanone Cleistanone, preparation method and in the purposes prepared on anti-erythrocyte low property anemia medicine.The present invention has synthesized O (piperidyl) ethyl derivative of a new Cleistanone Cleistanone, and discloses its preparation method.Pharmacological experiment shows, O (piperidyl) ethyl derivative of the Cleistanone Cleistanone of the present invention has the effect of anti-erythrocyte low property anemia, has the value of exploitation anti-erythrocyte low property anemia medicine.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to Cleistanone Cleistanone's
O-(piperidyl) ethyl derivative, preparation method and its usage.
Background technology
Based on different clinical characters, anemia has different classification.As: divide acute and chronic by anemia tempo
Anemia；Divide hyperplastic anemia (as thin in hemolytic anemia, iron deficiency anemia, huge children by bone marrow red system proliferative conditions
Born of the same parents' anemia etc.) and Hypolasia anemia (such as aplastic anemia).
Clinically often from anemia pathogenesis and the classification of the cause of disease:
1. erythropoiesis minimizing property anemia
The anomalous effects erythropoiesis of hematopoietic cell, marrow stromal cell and hemopoietic raw material, can be formed red carefully
Born of the same parents generate minimizing property anemia.
(1) hematopoietic stem/progenitor cells caused by abnormal anemia
1) aplastic anemia (AA) AA is a kind of marrow hematopoiesis function failure disease, with primary and secondary
Hematopoietic stem/progenitor cells infringement relevant.The pathogenesis of parts whole blood cytopenia produces anti-bone with B cell
Myelocyte autoantibody, and then destroy or suppress myeloid element relevant.
2) pure red cell aplasia anemia (PRCA) PRCA refers to that bone marrow erythroid hematopoiesis stem/progenitor cells is subject to
To infringement, and then cause anemia.According to the cause of disease, this disease can be divided into congenital and posteriority two class.Congenital
PRCA i.e. Diamond-Blackfan syndrome, is caused by heredity；Posteriority PRCA include primary, continue
Send out two classes.Having scholar to find in part constitutional PRCA patients serum has self EPO or normoblast antibody.
Secondary cases PRCA mainly have medicine relationship type, infect relationship type (antibacterial and virus, as HPV B19,
Hepatitis virus etc.), autoimmune disease relationship type, lymphoproliferative disease relationship type is (such as thymoma, pouring
Bar tumor, plasma cell dyscrasia and Lymphocytic leukemia etc.) and acute aplastic crisis etc..
3) to be that ancestral does in a red system of class heritability thin for congenital dyserythropoietic anemia (CDA) CDA
Born of the same parents' optimum clone caused by abnormal, the refractory anemia that is characterized with red system ineffective hematopoiesis and paramophia.According to
Mode of inheritance, this disease can be divided into autosome hidden flight of steps leading to a palace hall genotype and dominant inheritance's type.
4) these disease hematopoietic stem/progenitor cells of hemopoietic system malignant clone disease there occurs the exception of matter, including
Myelodysplastic syndrome and all kinds of hematopoietic system cancer disease such as leukemia etc..The former is because of DH,
High hypertrophy, high apoptosis, hemolysis in situ occurs；The latter's neoplastic hyperplasia, low apoptosis and low differentiation, hemopoietic regulates
Also be affected so that normal mature erythrocytopenia and there is anemia.
(2) hematopoieticmicroenviron-ment caused by abnormal anemia
Hematopoieticmicroenviron-ment includes bone marrow matrix, stromal cell and cytokine.
1) bone marrow matrix and stromal cell impaired Anemia BMN, myelofibrosis, myelosclerosis,
The bone marrow neoplasms of marble extramedullary tumor disease sick, various and various infection or non-infectious osteomyelitis, all
Can be because of damage bone marrow matrix and stromal cell, hematopoieticmicroenviron-ment occurs abnormal and affects hemopoietic.
2) hematopoietic regulators horizontal abnormality Anemia stem cell factor (SCF), interleukin (IL),
Grain-monosystem colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), erythrocyte are raw
Cheng Su (EPO), thrombopoietin (TPO), PDGF (TGF), neoplasm necrosis
The factor (TNF) and interferon (IFN) etc. are respectively provided with positive negative regulation hemoposieis.Renal insufficiency, hepatopathy
Not enough with producing EPO when hypophysis or hypothyroidism etc.；Neoplastic disease or some virus infection can lure
Lead body and produce more hemopoietic negative regulatory factor such as TNF, IFN, inflammatory factor etc., all may result in chronic disease
Property anemia (ACD).
(3) hemopoietic insufficient raw material or Use barriers Anemia
Hemopoietic raw material refers to material necessary to hematopoietic cell proliferation, differentiation, metabolism, as protein, lipid,
Vitamin (folic acid, vitamin B12 etc.), trace element (ferrum, copper, zinc etc.) etc..Any one hemopoietic
Insufficient raw material or Use barriers all may cause erythropoiesis to reduce.
1) folic acid or vitamin B12 deficiency or Use barriers Anemia are led due to various physiology or pathological factor
Cause body folic acid or absolute or that shortage or Use barriers can cause the relatively megaloblastic anemia of vitamin B12.
2) iron deficiency and ferrum Use barriers anemia this be the most modal anemia.Iron deficiency and ferrum Use barriers
Affecting haemachrome synthesis, having such anemia is called haemachrome resulting anomaly anemia.The erythrocyte shape of such anemia
State diminishes, and central authorities' olistherozone expands, and belongs to microcytic hypochromic anemia.
2. hemolytic anemia (HA)
I.e. hematoclasis too much property anemia.
3. hemorrhagic anemia
Dividing acute and chronic according to speed of losing blood, chronic blood loss anemia often merges iron deficiency anemia.Can be divided into
Go out disorders of blood coagulation (such as idiopathic thrombocytopenic purpura, hemophilia and severe liver disease etc.) make peace non-go out
Disorders of blood coagulation (such as wound, tumor, tuberculosis, bronchiectasis, peptic ulcer, hemorrhoid and gynaecopathia etc.)
Caused two classes.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus
The potential drug obtaining high-efficiency low-toxicity has important value.
The compound Cleistanone Cleistanone that the present invention relates to is one and within 2011, delivers (Van Trinh Thi
Thanh et al.,2011.Cleistanone:A Triterpenoid from Cleistanthus indochinensis with
a New Carbon Skeleton.Volume2011,Issue22,Pages4108 4111, August2011)
Compound, we have carried out structural modification to compound Cleistanone Cleistanone, it is thus achieved that one new
O-(piperidyl) ethyl derivative of Cleistanone Cleistanone, and its anti-erythrocyte low property anemia is lived
Property evaluated, its have anti-erythrocyte low property anemia activity.
Summary of the invention
The invention discloses O-(piperidyl) ethyl derivative of a Cleistanone Cleistanone, its structure
For:
O-(piperidyl) ethyl derivative (III) of Cleistanone Cleistanone of the present invention can pass through following side
Prepared by method:
(1) Cleistanone Cleistanone (I) reacts with glycol dibromide and obtains Cleistanone Cleistanone
O-bromoethyl derivant (II)；
(2) O-bromoethyl derivant (II) of Cleistanone Cleistanone and piperidines generation substitution reaction system
Obtain O-(piperidyl) ethyl derivative (III) of Cleistanone Cleistanone.
The further preparation method of O-(piperidyl) ethyl derivative (III) of Cleistanone Cleistanone
For:
(1) 440mg compound Cleistanone Cleistanone (I) is dissolved in 10mL benzene, adds in solution
The tetrabutyl ammonium bromide of 0.04g, the glycol dibromide of 3.760g and 50% sodium hydroxide solution of 6mL；
Mixture stirs 24h at 25 degrees Celsius；After 24h, reactant liquor is poured in frozen water, use dichloromethane immediately
It is extracted twice, merges organic phase solution；Then to organic phase solution successively with water and saturated aqueous common salt washing 3
Secondary, then be dried with anhydrous sodium sulfate, last concentrating under reduced pressure is removed solvent and is obtained product crude product；Product crude product silicon
Gel column chromatography eluting, flowing is mutually: petroleum ether/acetone=100:1, v/v, collects yellow and concentrates elution band and get final product
Yellow solid to O-bromoethyl derivant (II) of Cleistanone Cleistanone.
(2) O-bromoethyl derivant (II) of the Cleistanone Cleistanone of 273mg is dissolved in 20mL
In the middle of acetonitrile, it is added thereto to the Anhydrous potassium carbonate of 345mg, the potassium iodide of 84mg and the piperidines of 852mg,
Mixture is heated to reflux 16h；Reactant liquor is poured in 20mL frozen water after terminating by reaction, uses equivalent dichloromethane
Alkane extracts three times, merges organic facies；Organic facies after merging with water and saturated aqueous common salt washing successively, then use
Anhydrous sodium sulfate is dried, and concentrating under reduced pressure is removed solvent and obtained product crude product；Product crude product silica gel column chromatography is purified,
Flowing is mutually: petroleum ether/acetone=100:0.5, v/v, collects yellow and concentrates elution band i.e. to obtain Cleistanone
The yellow gummy solid 157.0mg of O-(piperidyl) ethyl derivative (III) of Cleistanone.
Compound disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
It is an object of the invention to provide the compounds of this invention new application in pharmaceutical field.
The present invention relates to the compounds of this invention as the application in preparation treatment erythrocyte low property anemia medicine.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not had
Any restriction of body embodiment, but be defined in the claims.
Detailed description of the invention
The preparation of embodiment 1 compound Cleistanone Cleistanone
The preparation method of compound Cleistanone Cleistanone (I) is with reference to Crinis Carbonisatus such as Van Trinh Thi Thanh
Document (Van Trinh Thi Thanh et al., the 2011.Cleistanone:A Triterpenoid from of table
Cleistanthus indochinensis with a New Carbon Skeleton.Volume2011,Issue22,
Pages4108 4111, August2011) method.
The synthesis of O-bromoethyl derivant (II) of embodiment 2 Cleistanone Cleistanone
Compound I (440mg, 1.00mmol) is dissolved in 10mL benzene, in solution, adds tetrabutyl phosphonium bromide
Ammonium (TBAB) (0.04g), glycol dibromide (3.760g, 20.00mmol) and 50% hydrogen of 6mL
Sodium hydroxide solution.Mixture stirs 24h at 25 degrees Celsius.After 24h, reactant liquor is poured in frozen water, vertical
I.e. it is extracted twice with dichloromethane, merges organic phase solution.Then to organic phase solution successively with water and saturated food
Saline washs 3 times, then is dried with anhydrous sodium sulfate, and last concentrating under reduced pressure is removed solvent and obtained product crude product.Produce
Thing crude product silica gel column chromatography purification (flowing is mutually: petroleum ether/acetone=100:1, v/v), collects yellow and concentrates
Elution band i.e. obtains the yellow solid (344mg, 63%) of compound II.
1H NMR(500MHz,DMSO-d6) δ 5.04 (s, 1H), 4.82 (s, 1H), 3.94 (d, J=26.5Hz,
1H), 3.87 (d, J=26.5Hz, 2H), 3.57 (s, 2H), 2.40 (d, J=14.0Hz, 1H), 2.39 (d, J=
14.0Hz,1H),2.27(s,1H),2.21(s,1H),2.15(s,1H),1.82(s,1H),1.62(s,2H),1.57
(d, J=3.3Hz, 1H), 1.54 (d, J=3.3Hz, 1H), 1.50 (d, J=1.2Hz, 1H), 1.47 (d, J=1.2
Hz, 1H), 1.39 (d, J=15.3Hz, 2H), 1.34 (d, J=15.3Hz, 1H), 1.26 (dd, J=32.6,13.7
Hz, 4H), 1.13 (d, J=18.0Hz, 2H), 1.05 (s, 6H), 0.98 (s, 1H), 0.88 (s, 12H), 0.78 (s,
3H),0.74(s,1H)。
13C NMR(125MHz,DMSO-d6)δ216.59(s),154.50(s),105.23(s),74.63(s),
69.85(s),59.71(s),52.55(s),51.21(s),47.92(s),44.10(s),42.25(s),41.73(s),
40.64 (s), 40.16 (s), 38.88 (s), 38.65 (s), 37.21 (s), 36.23 (s), 33.34 (d, J=1.1Hz),
32.96(s),29.91(s),27.18(s),26.03(s),24.23(s),23.96(s),20.77(s),18.48(s),
17.98(s),16.93(s)。
HRMS(ESI)m/z[M+H]+calcd for C32H52BrO2:547.3151；found547.3159.
The synthesis of O-(piperidyl) ethyl derivative (III) of embodiment 3 Cleistanone Cleistanone
Compound II (273mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, is added thereto to anhydrous carbon
Acid potassium (345mg, 2.5mmol), potassium iodide (84mg, 0.5mmol) and piperidines (852mg, 10mmol),
Mixture is heated to reflux 16h.Reactant liquor is poured in 20mL frozen water after terminating by reaction, uses equivalent dichloromethane
Alkane extracts three times, merges organic facies.Organic facies after merging with water and saturated aqueous common salt washing successively, then use
Anhydrous sodium sulfate is dried, and concentrating under reduced pressure is removed solvent and obtained product crude product.Product crude product silica gel column chromatography is purified
(flowing is mutually: petroleum ether/acetone=100:0.5, v/v), collects yellow and concentrates elution band i.e. to obtain Cleistanone
The yellow gummy solid (157.0mg, 57%) of O-(piperidyl) ethyl derivative.
1H NMR(500MHz,DMSO-d6)δ5.04(s,1H),4.85(s,1H),4.37(s,1H),3.54(s,2H),
2.57 (s, 2H), 2.47 (dd, J=44.3,41.4Hz, 6H), 2.29 (s, 1H), 2.22 (s, 1H), 2.19 (s, 1H),
1.82 (s, 1H), 1.65 (s, 2H), 1.58 (d, J=8.0Hz, 2H), 1.53 1.46 (m, 6H), 1.39 (t, J=
7.8Hz, 5H), 1.30 (dd, J=21.8,9.9Hz, 4H), 1.16 (d, J=0.4Hz, 2H), 1.06 (s, 6H),
0.91(s,1H),0.88(s,12H),0.85–0.57(m,4H).
13C NMR(125MHz,DMSO-d6)δ216.69(s),154.70(s),105.53(s),74.75(s),67.02
(s), 59.85 (s), 55.00 (d, J=14.4Hz), 52.87 (s), 51.30 (s), 48.09 (s), 44.44 (s), 42.38
(s),41.98(s),40.93(s),40.25(s),39.07(s),38.99(s),37.34(s),36.48(s),33.66(s),
33.05(s),30.10(s),27.52(s),26.16(s),24.80(s),24.59(s),24.06(s),23.65(s),
21.05(s),18.56(s),18.21(s),17.28(s).
HRMS(ESI):m/z[M+H]+calcd for C37H62NO2:552.4781；found:552.4787.
O-(piperidyl) the ethyl derivative anti-erythrocyte low property anemia experiment of embodiment 4 Cleistanone
Test O-(piperidyl) ethyl derivative of the 1 Cleistanone therapeutical effect to post hemorrhagic mice
ICR mice 30, ♀ ♂ half and half, it is divided into 3 groups (n=10).In addition to normal saline group, other group
Every mice, from orbital vein blood-letting 0.5ml, takes blood again and surveys whole index of respectively organizing, then continuous gavage after 24h
Blood-letting every day 0.5ml after being administered (0.1mL/10g body weight) 1 week and being administered, after last is administered 1h, from eye
Socket of the eye venous plexus takes the full whole bliid platelet analyzer of blood F-800 and carries out red blood cell count(RBC) (1012/L)。
O-(piperidyl) ethyl derivative of table 1 Cleistanone is made because of caused oligocythemic treatment of losing blood
With
Compare with model group: * p < 0.05
Result shows, blood-letting mice is treated after 7 days through O-(piperidyl) ethyl derivative taking Cleistanone,
Comparing with model group, its erythrocyte is significantly higher than model group, close to normal saline group.
Two, O-(piperidyl) ethyl derivative of Cleistanone causes oligocythemic treatment work to cyclophosphamide
With
Preventive and therapeutic effect ICR mice 30 to the damage of mouse bone marrow cells hemopoietic function, ♀ ♂ dual-purpose, it is divided into 3
Group (n=10), i.e. O-(piperidyl) the ethyl derivative 1.2mg/kg of normal saline group, modeling group, Cleistanone
Group, oral administration, every day 1 time.In addition to normal saline group, other respectively organized mice respectively on 0th, 5,10th
Lumbar injection cycli phosphate amine 80mg/kg, then proceedes to be administered 3 days.1h after last is administered, quiet from eye socket
Arteries and veins clump takes blood, surveys RBC number (1012/L)。
O-(piperidyl) the ethyl derivative impact erythrocytic on caused by cyclophosphamide of table 2 Cleistanone
Compare with model group: * * p < 0.01
Result shows, compares with normal saline group, and cycli phosphate amine can make mouse bone marrow cells damage, and causes peripheral blood thin
Born of the same parents decline, and O-(piperidyl) the ethyl derivative group of Cleistanone compares with model group, can substantially resist ring phosphorus
Acid amide induced mice red blood cell decreased.
Three, O-(piperidyl) ethyl derivative of Cleistanone is to therapeutical effect oligocythemic caused by benzene
Impact on Induced Aplastic Anemia Mice: Kunming mouse 30, ♀ ♂ dual-purpose, it is divided into 3 groups
(n=10), in addition to normal saline group, other organizes mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, modeling
The same day, oral administration simultaneously, every day 1 time, totally 18 days, last be administered after 1h, orbital venous plexus takes blood,
Survey erythrocyte.
O-(piperidyl) ethyl derivative of table 3 Cleistanone is to therapeutical effect oligocythemic caused by benzene
Compare with model group: * * p < 0.01
Result shows, administration group compares with model group, can substantially resist Induced Aplastic Anemia Mice caused by benzene red
The decline of cell.
O-(piperidyl) ethyl derivative of conclusion: Cleistanone can significantly raise erythrocyte, can be used to
The medicine of preparation treatment anemia.
Embodiment 5 compound involved in the present invention II and the preparation of III tablet
Take in the middle of O-(piperidyl) ethyl derivative or its pharmaceutically acceptable salt of 20 grams of Cleistanone
One, addition prepares the customary adjuvant 180 grams of tablet, and mixing, conventional tablet presses makes 1000.
Embodiment 6 compound involved in the present invention II and the preparation of III capsule
Take in the middle of O-(piperidyl) ethyl derivative or its pharmaceutically acceptable salt of 20 grams of Cleistanone
One, addition prepares the customary adjuvant such as starch 180 grams of capsule, mixing, encapsulated makes 1000.
Claims (4)
1. O-(piperidyl) ethyl derivative (III) of a Cleistanone Cleistanone with structure shown in formula III
And the application that pharmaceutically acceptable salt is in preparation treatment erythrocyte low property anemia medicine, it is characterized by:
Described erythrocyte low property anemia is caused by losing blood,
2. O-(piperidyl) ethyl derivative (III) of a Cleistanone Cleistanone with structure shown in formula III
And the application that pharmaceutically acceptable salt is in preparation treatment erythrocyte low property anemia medicine, it is characterized by:
Described erythrocyte low property anemia is low by the erythrocyte caused by chemical substance,
A kind of O-(piperazine of the Cleistanone Cleistanone with structure shown in formula III
Piperidinyl) ethyl derivative (III) and pharmaceutically acceptable salt thereof be at preparation treatment erythrocyte low property anemia medicine
In application, it is characterized by: described chemical substance is benzene, described erythrocyte low property anemia is by caused by benzene
Aplastic anemia.
A kind of O-(piperazine of the Cleistanone Cleistanone with structure shown in formula III
Piperidinyl) ethyl derivative (III) and pharmaceutically acceptable salt thereof be at preparation treatment erythrocyte low property anemia medicine
In application, it is characterized by: described chemical substance is cycli phosphate amine, described erythrocyte low property anemia is by ring
Red blood cell decreased caused by phosphamide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410375041.9A CN104127421B (en) | 2014-07-31 | 2014-07-31 | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410375041.9A CN104127421B (en) | 2014-07-31 | 2014-07-31 | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104127421A CN104127421A (en) | 2014-11-05 |
| CN104127421B true CN104127421B (en) | 2016-12-07 |
Family
ID=51800445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410375041.9A Active CN104127421B (en) | 2014-07-31 | 2014-07-31 | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127421B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758295A (en) * | 2015-03-10 | 2015-07-08 | 南京大学 | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug |
| CN104800222A (en) * | 2015-04-29 | 2015-07-29 | 南京大学 | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparing drug for preventing red blood cell hypoplastic anemia |
| CN104922123A (en) * | 2015-05-27 | 2015-09-23 | 南京大学 | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia |
| CN105616403A (en) * | 2015-07-16 | 2016-06-01 | 南京海澳斯生物医药科技有限公司 | Composition and application thereof to low red blood cell anemia resisting medicine |
| CN105395555A (en) * | 2015-11-05 | 2016-03-16 | 南京海澳斯生物医药科技有限公司 | Composition and application thereof to medicine resistant to red cell hypoplastic anemia |
| CN105250258A (en) * | 2015-11-09 | 2016-01-20 | 南京广康协生物医药技术有限公司 | Composition and application of composition in medicine for resistance of erythrocyte low anemia |
| CN105343083A (en) * | 2015-12-07 | 2016-02-24 | 南京海澳斯生物医药科技有限公司 | Composition and application of composition in medicines for resisting low erythrocyte anemia |
| CN106074528A (en) * | 2016-05-24 | 2016-11-09 | 南京海澳斯生物医药科技有限公司 | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-erythrocyte low property anaemia medicine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101123880B (en) * | 2004-09-07 | 2011-06-08 | 太平洋艾瑞有限公司 | Anti-tumor compounds with angeloyl groups |
-
2014
- 2014-07-31 CN CN201410375041.9A patent/CN104127421B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104127421A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127421B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104083385B (en) | The application in the medicine preparing leukocyte increasing of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104147014B (en) | The application in preparing anti-erythrocyte low property anemia medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN104288159B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN104083383B (en) | The application in preparing anti-acute renal failure medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104800222A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparing drug for preventing red blood cell hypoplastic anemia | |
| CN105078985A (en) | Composition 53083001030571 and application of composition 53083001030571 to drug for resisting low-hematocrit anemia | |
| CN104922123A (en) | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia | |
| CN105250308A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105250293A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN104887667A (en) | Application of Daphmalenine A ramification to preparing medicine for resisting low red blood cell anemia | |
| CN105287570A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105250258A (en) | Composition and application of composition in medicine for resistance of erythrocyte low anemia | |
| CN105193815A (en) | Composition and application thereof in drugs for preventing low-erythrocyte anemia | |
| CN106038551A (en) | Application of composition of Schiglautone A derivatives in preparation of low-erythrocyte anemia preventive drugs | |
| CN104758295A (en) | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug | |
| CN105287525A (en) | Composition and application of composition in medicine for resisting low red blood cell type anemia | |
| CN105935361A (en) | Application of composition of Virosaine A tetrahydropyrrole and morpholinyl derivatives in drugs for resisting low red blood cell anemia | |
| CN105343083A (en) | Composition and application of composition in medicines for resisting low erythrocyte anemia | |
| CN105616403A (en) | Composition and application thereof to low red blood cell anemia resisting medicine | |
| CN107929288A (en) | The miscellaneous source terpene piperazinyl of guava dialdehyde and tetrazole radical derivative composition are used to prepare anti-anemia action medicine | |
| CN105853430A (en) | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia | |
| CN105343085A (en) | Composition and application thereof in low erythrocyte anemia resistant drugs | |
| CN105497038A (en) | Composition and application thereof to low-erythrocyte anemia resistant medicament | |
| CN105287455A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160923 Address after: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant after: Gu Yukui Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing guangkangxie Biomedical Technology Co.,Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yidong Inventor after: Zhong Liangxiao Inventor after: Yu Dan Inventor after: Wu Shaojing Inventor before: Wu Junyi Inventor before: Jiang Chunping Inventor before: Wu Junhua |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 210000 No. 215 Guangzhou Road, Gulou District, Nanjing City, Jiangsu Province Patentee after: Gu Yukui Address before: 266000 No. nine water East Road, Licang District, Qingdao, Shandong, 320 Patentee before: Gu Yukui |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191021 Address after: 314000 NO.3-4, yuejingzhuang erjiefang, no.1508, ziye East Road, Wuzhen Town, Tongxiang City, Jiaxing City, Zhejiang Province Patentee after: Tanjiawan Heritage Park Operation Management (Wuzhen, Tongxiang) Co.,Ltd. Address before: 210000 Guangzhou Road, Drum Tower District, Nanjing, Jiangsu Province, No. 215 Patentee before: Gu Yukui |
|
| TR01 | Transfer of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20230609 Granted publication date: 20161207 |
|
| PP01 | Preservation of patent right |